SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
Sen. Bernie Sanders (I-Vt.) speaks during a rally protesting high prescription drug prices on September 21, 2021.
(Photo: Tom Williams/CQ-Roll Call, Inc. via Getty Images)
Sanders Raises Fresh Concerns Over 'Outrageous' Price of New Alzheimer's Drug
"Not only does the high price of Leqembi threaten Medicare's finances, it will also negatively impact seniors on fixed incomes suffering from Alzheimer’s who simply cannot afford to pay."
Jul 10, 2023
Sen. Bernie Sanders on Monday reiterated his concerns over the staggering price tag of a newly approved Alzheimer's medication after the Biden administration failed to respond to his letter last month urging swift executive action to force down the cost.
In a new letter to Health and Human Services Secretary Xavier Becerra, Sanders (I-Vt.) wrote that the current $26,500 list price for Leqembi is "outrageous" and demanded that the Biden administration explain "why the cost of this drug cannot be reduced to $8,900—which is the price independent experts believe it should cost based on its effectiveness."
Sanders, the chair of the Senate Health, Education, Labor, and Pensions (HELP) Committee, raised particular alarm over the drug's possible impact on Medicare's finances.
Shortly after the Food and Drug Administration (FDA) approved Leqembi last week, the Centers for Medicare and Medicaid Services announced that Medicare will cover the treatment "broadly"—a contrast from its decision last year to limit coverage of Aduhelm, a different high-priced Alzheimer's drug.
KFF estimates that if 5% of people with Alzheimer's disease use Leqembi—also known as lecanemab—Medicare's annual outlays for the IV infusion treatment would be $8.9 billion, a spending increase that could push premiums up for all Medicare recipients.
As Sanders wrote, "Not only does the high price of Leqembi threaten Medicare's finances, it will also negatively impact seniors on fixed incomes suffering from Alzheimer’s who simply cannot afford to pay the 20% co-payment of more than $5,000 a year for this drug."
"With a median income of about $30,000 a year for seniors on Medicare the purchase of this one drug would amount to over one-
sixth of their limited income. For one drug! That is unacceptable," the senator continued. "A prescription drug is not effective if a patient who needs that drug cannot afford it."
"If I do not receive an adequate and timely response, I will be inviting you to attend a HELP Committee hearing so that you can explain to the American people why we pay, by far, the highest prices in the world for prescription drugs."
Sanders first wrote to the Biden administration about Leqembi's cost on June 7, when he warned that the price tag proposed by manufacturers Biogen and Eisai was "unconscionable" and "grossly unfair to seniors suffering from Alzheimer's disease."
But Becerra never responded to Sanders' June letter, the senator wrote Monday.
Sanders requested in his new letter that Becerra provide answers to the fresh series of questions by July 21.
Among the questions Sanders wants answered is whether Becerra is "prepared to use [his] existing authority, under 28 U.S.C. Section 1498, to break the patent monopoly on exorbitantly priced prescription drugs."
"If I do not receive an adequate and timely response," Sanders wrote, "I will be inviting you to attend a HELP Committee hearing so that you can explain to the American people why we pay, by far, the highest prices in the world for prescription drugs and how those outrageous prices threaten Medicare beneficiaries and patients throughout the country."
On top of concerns about its potential harms to Medicare's financial health, experts and consumer advocates have said they're worried about the Leqembi's effectiveness and safety for Alzheimer’s patients, citing the drug's impacts on some trial subjects.
Dr. Robert Steinbrook, director of Public Citizen's Health Research Group, said in a statement last week that "the FDA's decision to grant full approval for lecanemab to treat adult patients with Alzheimer’s disease is misguided and very disappointing."
"The evidence for the drug's clinical benefits does not outweigh its substantial health risks," Steinbrook argued. "The fact that a black box warning for brain swelling and bleeding risks has been added to the prescribing information for lecanemab underscores the substantial safety concerns."
"Patients with Alzheimer's disease and their families are understandably desperate for better treatments," he added. "When it approves drugs for Alzheimer's disease with little or no benefit and significant health risks, the FDA fails patients and the public."
An Urgent Message From Our Co-Founder
Dear Common Dreams reader, It’s been nearly 30 years since I co-founded Common Dreams with my late wife, Lina Newhouser. We had the radical notion that journalism should serve the public good, not corporate profits. It was clear to us from the outset what it would take to build such a project. No paid advertisements. No corporate sponsors. No millionaire publisher telling us what to think or do. Many people said we wouldn't last a year, but we proved those doubters wrong. Together with a tremendous team of journalists and dedicated staff, we built an independent media outlet free from the constraints of profits and corporate control. Our mission has always been simple: To inform. To inspire. To ignite change for the common good. Building Common Dreams was not easy. Our survival was never guaranteed. When you take on the most powerful forces—Wall Street greed, fossil fuel industry destruction, Big Tech lobbyists, and uber-rich oligarchs who have spent billions upon billions rigging the economy and democracy in their favor—the only bulwark you have is supporters who believe in your work. But here’s the urgent message from me today. It's never been this bad out there. And it's never been this hard to keep us going. At the very moment Common Dreams is most needed, the threats we face are intensifying. We need your support now more than ever. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. When everyone does the little they can afford, we are strong. But if that support retreats or dries up, so do we. Will you donate now to make sure Common Dreams not only survives but thrives? —Craig Brown, Co-founder |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
Sen. Bernie Sanders on Monday reiterated his concerns over the staggering price tag of a newly approved Alzheimer's medication after the Biden administration failed to respond to his letter last month urging swift executive action to force down the cost.
In a new letter to Health and Human Services Secretary Xavier Becerra, Sanders (I-Vt.) wrote that the current $26,500 list price for Leqembi is "outrageous" and demanded that the Biden administration explain "why the cost of this drug cannot be reduced to $8,900—which is the price independent experts believe it should cost based on its effectiveness."
Sanders, the chair of the Senate Health, Education, Labor, and Pensions (HELP) Committee, raised particular alarm over the drug's possible impact on Medicare's finances.
Shortly after the Food and Drug Administration (FDA) approved Leqembi last week, the Centers for Medicare and Medicaid Services announced that Medicare will cover the treatment "broadly"—a contrast from its decision last year to limit coverage of Aduhelm, a different high-priced Alzheimer's drug.
KFF estimates that if 5% of people with Alzheimer's disease use Leqembi—also known as lecanemab—Medicare's annual outlays for the IV infusion treatment would be $8.9 billion, a spending increase that could push premiums up for all Medicare recipients.
As Sanders wrote, "Not only does the high price of Leqembi threaten Medicare's finances, it will also negatively impact seniors on fixed incomes suffering from Alzheimer’s who simply cannot afford to pay the 20% co-payment of more than $5,000 a year for this drug."
"With a median income of about $30,000 a year for seniors on Medicare the purchase of this one drug would amount to over one-
sixth of their limited income. For one drug! That is unacceptable," the senator continued. "A prescription drug is not effective if a patient who needs that drug cannot afford it."
"If I do not receive an adequate and timely response, I will be inviting you to attend a HELP Committee hearing so that you can explain to the American people why we pay, by far, the highest prices in the world for prescription drugs."
Sanders first wrote to the Biden administration about Leqembi's cost on June 7, when he warned that the price tag proposed by manufacturers Biogen and Eisai was "unconscionable" and "grossly unfair to seniors suffering from Alzheimer's disease."
But Becerra never responded to Sanders' June letter, the senator wrote Monday.
Sanders requested in his new letter that Becerra provide answers to the fresh series of questions by July 21.
Among the questions Sanders wants answered is whether Becerra is "prepared to use [his] existing authority, under 28 U.S.C. Section 1498, to break the patent monopoly on exorbitantly priced prescription drugs."
"If I do not receive an adequate and timely response," Sanders wrote, "I will be inviting you to attend a HELP Committee hearing so that you can explain to the American people why we pay, by far, the highest prices in the world for prescription drugs and how those outrageous prices threaten Medicare beneficiaries and patients throughout the country."
On top of concerns about its potential harms to Medicare's financial health, experts and consumer advocates have said they're worried about the Leqembi's effectiveness and safety for Alzheimer’s patients, citing the drug's impacts on some trial subjects.
Dr. Robert Steinbrook, director of Public Citizen's Health Research Group, said in a statement last week that "the FDA's decision to grant full approval for lecanemab to treat adult patients with Alzheimer’s disease is misguided and very disappointing."
"The evidence for the drug's clinical benefits does not outweigh its substantial health risks," Steinbrook argued. "The fact that a black box warning for brain swelling and bleeding risks has been added to the prescribing information for lecanemab underscores the substantial safety concerns."
"Patients with Alzheimer's disease and their families are understandably desperate for better treatments," he added. "When it approves drugs for Alzheimer's disease with little or no benefit and significant health risks, the FDA fails patients and the public."
Sen. Bernie Sanders on Monday reiterated his concerns over the staggering price tag of a newly approved Alzheimer's medication after the Biden administration failed to respond to his letter last month urging swift executive action to force down the cost.
In a new letter to Health and Human Services Secretary Xavier Becerra, Sanders (I-Vt.) wrote that the current $26,500 list price for Leqembi is "outrageous" and demanded that the Biden administration explain "why the cost of this drug cannot be reduced to $8,900—which is the price independent experts believe it should cost based on its effectiveness."
Sanders, the chair of the Senate Health, Education, Labor, and Pensions (HELP) Committee, raised particular alarm over the drug's possible impact on Medicare's finances.
Shortly after the Food and Drug Administration (FDA) approved Leqembi last week, the Centers for Medicare and Medicaid Services announced that Medicare will cover the treatment "broadly"—a contrast from its decision last year to limit coverage of Aduhelm, a different high-priced Alzheimer's drug.
KFF estimates that if 5% of people with Alzheimer's disease use Leqembi—also known as lecanemab—Medicare's annual outlays for the IV infusion treatment would be $8.9 billion, a spending increase that could push premiums up for all Medicare recipients.
As Sanders wrote, "Not only does the high price of Leqembi threaten Medicare's finances, it will also negatively impact seniors on fixed incomes suffering from Alzheimer’s who simply cannot afford to pay the 20% co-payment of more than $5,000 a year for this drug."
"With a median income of about $30,000 a year for seniors on Medicare the purchase of this one drug would amount to over one-
sixth of their limited income. For one drug! That is unacceptable," the senator continued. "A prescription drug is not effective if a patient who needs that drug cannot afford it."
"If I do not receive an adequate and timely response, I will be inviting you to attend a HELP Committee hearing so that you can explain to the American people why we pay, by far, the highest prices in the world for prescription drugs."
Sanders first wrote to the Biden administration about Leqembi's cost on June 7, when he warned that the price tag proposed by manufacturers Biogen and Eisai was "unconscionable" and "grossly unfair to seniors suffering from Alzheimer's disease."
But Becerra never responded to Sanders' June letter, the senator wrote Monday.
Sanders requested in his new letter that Becerra provide answers to the fresh series of questions by July 21.
Among the questions Sanders wants answered is whether Becerra is "prepared to use [his] existing authority, under 28 U.S.C. Section 1498, to break the patent monopoly on exorbitantly priced prescription drugs."
"If I do not receive an adequate and timely response," Sanders wrote, "I will be inviting you to attend a HELP Committee hearing so that you can explain to the American people why we pay, by far, the highest prices in the world for prescription drugs and how those outrageous prices threaten Medicare beneficiaries and patients throughout the country."
On top of concerns about its potential harms to Medicare's financial health, experts and consumer advocates have said they're worried about the Leqembi's effectiveness and safety for Alzheimer’s patients, citing the drug's impacts on some trial subjects.
Dr. Robert Steinbrook, director of Public Citizen's Health Research Group, said in a statement last week that "the FDA's decision to grant full approval for lecanemab to treat adult patients with Alzheimer’s disease is misguided and very disappointing."
"The evidence for the drug's clinical benefits does not outweigh its substantial health risks," Steinbrook argued. "The fact that a black box warning for brain swelling and bleeding risks has been added to the prescribing information for lecanemab underscores the substantial safety concerns."
"Patients with Alzheimer's disease and their families are understandably desperate for better treatments," he added. "When it approves drugs for Alzheimer's disease with little or no benefit and significant health risks, the FDA fails patients and the public."
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.